We used a retrospective modeling approach instead of the traditional farm to fork model; back calculating (Cm) the number of human macrolide resistant C. coli mfections caused by eating contaminated pork, due to specific macrolide use in swine. We used the estimated number of culture confirmed human infections (Ct). As a measure of human health risk, we then calculated the expected number among the (Cm) cases that experience an adverse treatment outcome (prolonged illness) due to macrolide resistance , using estimates for fluoroqu inolone. We divided the model into Release, Exposure and Consequence assessment sections according to FDA guidance 152 and utilized @Risk software with 20,000 iterations for simulation . The results show the human health risks are negligible. For example, the predicted annual risk, for preventton and growth promotion uses is only 1 in 92 million per U.S. resident, with a 5% chance it could be as high as 1 in 52 million. Our model focuses on the impact of resistance on human treatment. It assumes that macrolide resistance C. coli infection reduces treatment efficacy. However, it is possible that risks less than our estimates.
Introduction
Campylobacter is considered an important food -borne pathogen. Erythromycin. a macrolide antibiottc, is recommended for the treatment and control of severe culture confirmed campylobacteriosis. Recent studies have reported higher frequencies of resistant Campylobacter in conventional swine farms compared to antibiotic free farms . There are concerns that macrolide antibiotic use on swine farms may increase human health risk. Our objective was to conduct a stochastic quantitative risk assessment of potential adverse health outcomes due to macrolide resistant C. coli infection originating from macrolide use on the swine farm.
Materials and Methods
We chose a retrospective modeling approach instead of the traditional farm to fork model wh ich is significantly more data intensive. Hence, we back calculated (Cm) the number of human macrolide resistant C. coli infections caused by eating contaminated pork, due to a specific type of macrolide use in swine. We started with estimated number of total culture confirmed human tnfections (Ct).
As a measure of human health risk , we then calculated the expected number among the Cm cases that might experience an adverse treatment outcome due to macrolide resistance. An adverse treatment outcome refers to ineffective treatment resulting in prolonged illness such as extra days of diarrhea or fever. We divided our model into Release, Exposure and Consequence assessment secttons according to FDA guidance 152 (www. fda .qov/cvm/guidance/fquide152 DOC). We utilized a variety of uncertainty distributions for the parameters and simulated with @Risk software (20,000 iterations).
Release Assessment:
In th is section , we calculated the fraction of C. coli population 1n swine that is macrolide resistant due to different types of macrolide (rm). Following we describe the estimatton of rm for prevention and growth promotion uses (Tylan Premix® and Tylan Sulfa-G ®) followed by the estimation for treatment and control uses (Tylan Injection®, Tylan Soluble® and Pulmotil Premix®)
Let rb be the background resistant fraction that exists without exposure to macrolide, and r1 be the steady state resistant fraction in a conventional farm in which a fraction (a) of the swine have been exposed to a specific macrolide. The total resistant fraction (r1) is linearly related to the fract1on exposed (a) as a first order approximation shown m Equation 1.
(1)
Where , the constant (p) corresponds to the probability that a bacterium among the fraction a(1-rb) of the C. coli population that is susceptible, acquires res1stance or 1s replaced by a resistant bactenum. The term a(1-rb)P IS equal to (rm). the fraction resistant due to macrolide use To est1mate p, we used the difference 1n the resistant fractions between antib1otic free (ABF) farms and conventional farms (using macrol1de). Two studies reported 38% of 745 C coli isolates from ABF farms and 77% of 347 C. coli Isolates from conventional farms (r1) were resistant (Gebreyes et al , 2005 and Thakur and Gebreyes 2005) . Hence, we estimated rb = 38% and r, = 77% (Mean of the Beta distributions in Table 2 ). We assumed that all the animals in the conventiona l farms were exposed to macrolide i.e. a =1 . By solving Equation 1, we calculated p = 62% for prevention and growth promotion uses. From industrial usage data , the overall national fraction of swine exposed for prevention and growth promotion uses was 58% (Doane, 2005) . Finally, we computed, rm=21% (resistance in C. coli 1n sw1ne that 1s due to macrolide use).
For estimation of p due to treatment uses, we had to use data on Enterococci spp. Jackson et al , 2004 found that the resistant fraction in Enterococci spp. from farms that used macrolide for prevent1on alone was tw1ce of that 1n farms with treatment uses. Therefore, we assumed (p) for treatment uses is 31% or half of the (p) for prevention or growth promotion uses.
Exposure assessment: For the Exposure assessment, we estimated the number of cultureconfirmed human C. coli infections that are resistant due to macrolide use 1n swme (Cm) utilizing Equation 2.
Where , the population etiologic fraction (17) is defined as the fraction of human mfect1ons caused by C. coli from swme. Total number of culture confirmed human C. coli infections per year is C1• To calculate the etiolog1c fraction (17) for sw1ne, we conservatively (Risk increasing) assumed that all the C. coli infections (C1) are caused by eating only chicken or pork, then distributed the cases according to relat1ve carcass contamination rates . Table 1 provides the data sources, and the estimated values of the parameters utilized in calculating f] . To estimate the kilograms of contam1nated pork, we assumed that all ground pork from a contaminated sw1ne carcass is contaminated , while the non ground pork is not. For kilograms of contaminated chicken we assumed all serv1ngs from a contaminated carcass were contaminated As a result, we calculated that 12.4% of the human C. coli Infections are caused from swine. 
.3 btllion
Consequence assessment: We calculated the annual number of adverse outcomes due to macrolide use (Cao) according to Equation 3. Where r is the joint probability that a culture confirmed infection is treated with an antibiotic and the prescribed antibiotic is macrolide The parameter, p, IS the probability that adverse outcome occurs due to macrolide resistance.
(3)
We are unaware of any evidence that macrolide resistant Campylobacter causes any more illness days than susceptible or that erythromycin treatment has any clinical benefit, i e. p is likely zero. However, to be conservative, we utilized fluoroquinolone data to estimate p; erroneously assuming that macrolide and fluoroquinolone resistant 1nfect1ons have identical clinical consequences. Gupta et al , 2004 Nelson et al., 2004 Kushner et al • 1995 Sanders et al , 2002 Confidence Intervals provided are two sided at 90% confidence The human health consequences are g1ven as med1ans Annual nsk was calculated as the ratio of the US populat1on of 298 millton/Cao • These are uncerta1nty d1stnbulions for the parameter estimates wh1ch were Simulated us1ng @R1 sk® software
Results

fS
The parameter estimates, their distributions, data sources, the results for the risk assessment are @ summarized in Table 2 . The median risk of an adverse treatment outcome due to macrolide use oJ= induced resistance in C. coli from swine is less than 1 in 80 million. The risk is less than 1 in 45 million with 95%. The risk due to treatment uses is negligible and is less than 1 in 354 million with 95% confidence.
Discussion
Our results show that at worst, the human health risk due to macrolide induced resistance in C. coli from swine is very low even with the conservative assumptions we made. Reasons for the low risk include the low fraction of human infections caused by C. coli and the relatively higher C. coli contamination rate of chicken carcass. Furthermore, the risk due to treatment uses is negligible as only a very small fraction of swine is exposed to it. We had to make very conservative assumptions such as that all the C. coli infections are caused from chicken or swine due to the lack of data on the etiologic fraction. More data on the etiologic fraction and the clinical consequences of erythromycin resistance is required . In addition, Sensitivity analysis showed that the fraction of human infections caused by C. coli and macrolide resistant fractions in conventional and ABF farms are other parameters leading to a significant uncertainty in the resulting risk estimates, demonstrating the need for further research in this area.
